<DOC>
	<DOCNO>NCT02468557</DOCNO>
	<brief_summary>This study evaluate safety , pharmacodynamics , pharmacokinetics ( PK ) , efficacy single agent idelalisib combination chemotherapy adult metastatic pancreatic ductal adenocarcinoma . This study also define maximum tolerate dose ( MTD ) idelalisib combination chemotherapy .</brief_summary>
	<brief_title>Study Single Agent Idelalisib Followed Idelalisib Combination With Chemotherapy Adults With Metastatic Pancreatic Ductal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>The presence metastatic pancreatic adenocarcinoma plus 1 following : Histological diagnosis pancreatic adenocarcinoma confirm pathologically , OR Pathologist confirm histological/cytological diagnosis adenocarcinoma consistent pancreas origin Measurable disease per RECIST v1.1 Prior systemic chemotherapy treatment metastatic pancreatic ductal adenocarcinoma ( Arm : idelalisib single agent ) Received one prior line chemotherapy metastatic pancreatic ductal adenocarcinoma ( Arm : idelalisib + mFOLFOX6 ) Adequate organ function define follow : Hepatic : Total bilirubin ≤ 1.25 x upper limit normal ( ULN ) ( Arm : idelalisib + nabpaclitaxel ) ; total bilirubin ≤1.5 x ULN ( Arm : single agent idelalisib Arm : idelalisib + mFOLFOX6 ) ; aspartate transaminase ( AST ) ( SGOT ) , alanine transaminase ( ALT ) ( SGPT ) &lt; 2.5 x ULN , albumin &gt; 3.0 g/dL Hematological : absolute neutrophil count ( ANC ) &gt; 1,500 cells/mm^3 , platelet &gt; 100,000 cells/mm^3 , hemoglobin &gt; 9.0 g/dL Renal : Serum creatinine ≤ 1.5 x ULN OR calculate creatinine clearance ( CrCl ) &gt; 30 ml/min calculate CockcroftGault method Able comprehend willing sign write informed consent form Currently previously treat biologic , immunotherapy Currently previously treat conventional chemotherapy , agent metastatic pancreatic ductal adenocarcinoma ( Arm : idelalisib + nabpaclitaxel ) Evidence ongoing systemic bacterial , fungal , viral infection time enrollment Known HIV infection History concurrent second malignancy except adequately treated local basal cell squamous cell carcinoma skin , cervical carcinoma situ , superficial bladder cancer , asymptomatic prostate cancer without know metastatic disease requirement therapy require hormonal therapy normal prostatespecific antigen ≥ 1 year prior enrollment , adequately treat Stage 1 2 nonpancreatic cancer currently complete remission , nonpancreatic cancer complete remission ≥ 5 year Diagnosis pancreatic islet neoplasm , acinar cell carcinoma , nonadenocarcinoma ( eg , lymphoma , sarcoma ) , adenocarcinoma originate biliary tree cystadenocarcinoma History serious allergic reaction , include anaphylaxis toxic epidermal necrolysis Presence peripheral neuropathy ≥ Grade 2 ( Arm : idelalisib + nabpaclitaxel Arm : idelalisib + mFOLFOX6 ) Documented myocardial infarction unstable/uncontrolled cardiac disease ( eg , unstable angina , congestive heart failure [ New York Heart Association &gt; Class III ] ) within 6 month enrollment Known hypersensitivity idelalisib , metabolite , formulation excipients Known hypersensitivity nabpaclitaxel ( Arm : idelalisib + nabpaclitaxel ) , metabolites , formulation excipients Known hypersensitivity 5fluorouracil , leucovorin , oxaliplatin ( Arm : idelalisib + mFOLFOX6 ) , metabolites , formulation excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Relapsed/refractory pancreatic ductal adenocarcinoma</keyword>
	<keyword>Previously untreated pancreatic ductal adenocarcinoma</keyword>
</DOC>